PMID- 10561324
OWN - NLM
STAT- MEDLINE
DCOM- 20000106
LR  - 20220408
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 17
IP  - 8
DP  - 1999 Aug
TI  - Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase 
      II clinical trials.
PG  - 2572-8
AB  - PURPOSE: To determine aggregate outcomes and prognostic covariates in patients 
      with recurrent glioma enrolled onto phase II chemotherapy trials. PATIENTS AND 
      METHODS: Patients from eight consecutive phase II trials included 225 with 
      recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic 
      astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their 
      median Karnofsky performance score was 80 (range, 60 to 100). Prognostic 
      covariates were analyzed with respect to tumor response, progression-free 
      survival (PFS), and overall survival (OS) by multivariate logistic and Cox 
      proportional hazards regression analyses. RESULTS: Overall, 34 (9%) had complete 
      or partial response, whereas 80 (21%) were alive and progression-free at 6 months 
      (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a 
      robust prognostic factor across all outcomes. GBM patients had significantly 
      poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31% for 
      AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were 
      also significantly poorer for patients with more than two prior surgeries or 
      chemotherapy regimens. CONCLUSION: Histology is a dominant factor in determining 
      outcome in patients with recurrent glioma enrolled onto phase II trials. Future 
      trials should be designed with separate histology strata.
FAU - Wong, E T
AU  - Wong ET
AD  - Departments of Neuro-Oncology and Biomathematics, The University of Texas M.D. 
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hess, K R
AU  - Hess KR
FAU - Gleason, M J
AU  - Gleason MJ
FAU - Jaeckle, K A
AU  - Jaeckle KA
FAU - Kyritsis, A P
AU  - Kyritsis AP
FAU - Prados, M D
AU  - Prados MD
FAU - Levin, V A
AU  - Levin VA
FAU - Yung, W K
AU  - Yung WK
LA  - eng
GR  - CA55621/CA/NCI NIH HHS/United States
GR  - CA62412/CA/NCI NIH HHS/United States
GR  - CA62431/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
CIN - J Clin Oncol. 2001 Oct 1;19(19):3997-9. PMID: 11579124
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Astrocytoma/classification/*drug therapy/*pathology
MH  - Brain Neoplasms/classification/*drug therapy/pathology
MH  - Glioblastoma/classification/*drug therapy/*pathology
MH  - Humans
MH  - Karnofsky Performance Status
MH  - Logistic Models
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Probability
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Salvage Therapy
MH  - Treatment Outcome
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.1200/JCO.1999.17.8.2572 [doi]
PST - ppublish
SO  - J Clin Oncol. 1999 Aug;17(8):2572-8. doi: 10.1200/JCO.1999.17.8.2572.